HIV-1 resistance testing influences treatment decision-making

HIV-1 resistance testing influences treatment decision-making

Author Diaz, Ricardo Sobhie Autor UNIFESP Google Scholar
Sucupira, Maria Cecilia A. Autor UNIFESP Google Scholar
Vergara, Tania R. C. Google Scholar
Brites, Carlos Google Scholar
Del Bianco, Rosana Google Scholar
Bonasser Filho, Francisco Google Scholar
Colares, Geova Keny B. Google Scholar
Portela, Estevao Google Scholar
Cherman, Lia Adler Google Scholar
Barcelos, Nemora Tregnago Google Scholar
Tupinambas, Unai Google Scholar
Turcato, Gilberto Google Scholar
Allamasey, Lisa Google Scholar
Bacheler, Lee Google Scholar
Tuohy, Martin Google Scholar
Brazilian Network Reference Phys W Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Universidade Federal da Bahia (UFBA)
Hosp Emilio Ribas
Univ Fortaleza
Fundacao Oswaldo Cruz
Secretaria Estadual Saude Rio Grande Sul
Universidade Federal de Minas Gerais (UFMG)
Virco BVBA
VircoLab Inc
Abstract Objective: To investigates how the use of HIV-1 resistance tests influences physician decision-making. Methods: Ten experienced reference physicians from the Brazilian Network for Drug Resistance each received ten patients' case histories. the selected patients had experienced at least two virological failures. First, reference physicians were asked to empirically select a new regimen for each patient. Second, after genotype report (ViroSeq 2.6) was provided, and physicians were again asked to select a new regimen considering this additional information. Finally, they were asked to select a regimen after receiving a virtual phenotype result (vircoTYPE 3.9.00). Results: in 79% of the cases, physicians changed their empirical choice of regimen after receiving the genotype report, resulting in an increase in the mean number of active drugs from 1.8 to 2.2 (p = 0.0003), while the average number of drugs/regimen remained at 4.0. After receipt of the virtual phenotype report, additional changes were made in 75% of the patient cases, resulting in an increase in the number of active drugs to 2.8 (p < 0.0001), while the average number of drugs/regimen remained at 4.0. After receipt of the genotype report, 48% of the changes were in NRTIs, 29% were in NNRTIs and 60% were in PIs; after consideration of the virtual phenotype, 61%, 10% and 49% of the changes, respectively, were in these categories of drugs. Fourteen percent of the physicians rated the genotype report as extremely useful, whereas 34% rated the subsequent virtual phenotype report as extremely useful (p = 0.0003). Conclusions: Resistance testing has a significant impact on physicians' choices of antiretroviral salvage therapies, and it promotes the selection of more active drugs.
Keywords genotype
virtual phenotype
antiretroviral resistance
Language English
Date 2010-09-01
Published in Brazilian Journal of Infectious Diseases. Salvador: Contexto, v. 14, n. 5, p. 489-494, 2010.
ISSN 1413-8670 (Sherpa/Romeo, impact factor)
Publisher Contexto
Extent 489-494
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000286107300011
SciELO ID S1413-86702010000500011 (statistics in SciELO)

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account